Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 6:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2113–2136 of 21,991 matching trials from the live ClinicalTrials.gov search.

Filters: Recruiting Clear all

Conditions: Localized Lung Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Electronic Health Record Review, Medical Device Usage and Evaluation, Questionnaire Administration, Respiratory Muscle Training, Sham Intervention; Procedure · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Glycogen Storage Disease, GSD Type 0A, GSD Type 0B, GSD VII, Tarui Disease, GSD X, GSD XII, GSD XIII, GSD XV, PGBM2, PRKAG2, Danon Disease, Polyglucosan Body Myopathy Type 1, Polyglucosan Body Myopathy Type 2, RBCK1 Deficiency
Interventions: No intervention; Other
Lead sponsor: Duke University; Other
Eligibility: 0 Years to 90 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2034
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hematologic Malignancies, Hematologic Neoplasms
Interventions: mCD19-CAR-CD28-CD3-zeta.(anti-CD19 CAR) retroviral vector-transduced allogeneic peripheral blood lymphocytes (PBL), Fludarabine, Cyclophosphamide, Mycophenolate Mofetil, Sirolimus, CD19 Flow Cytometry Assay, CD19 Immunohistochemical Assay, Total Body Irradiation; Biological · Drug · Device + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy, Insulin Resistance
Interventions: Neuromuscular Test, DEXA, Mixed Meal Tolerance Test, Strength Test; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 60 Years to 85 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Medical Oncology, Integrative Oncology, Medical Nutrition Therapy
Interventions: Diet; Other
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Buffalo, New York

Conditions: Acute Myeloid Leukemia
Interventions: Gemtuzumab Ozogamicin, Quality-of-Life Assessment, Bone Marrow Aspiration, Biospecimen Collection; Drug · Other · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Open Angle Glaucoma (OAG), Ocular Hypertension (OH)
Interventions: Travoprost; Combination Product
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Kenosha, Wisconsin

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: Female only
Enrollment: 1,182 participants
Timeline: 2022 – 2032
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Obesity, Overweight, Osteoarthritis of the Knee
Interventions: Berobenatide, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 656 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 39
States / cities: Tempe, Arizona • Escondido, California • Rancho Cucamonga, California + 30 more

Conditions: Angina Pectoris, Microvascular Angina, Vasospastic Angina, Myocardial Bridge of Coronary Artery
Interventions: Amlodipine, Nebivolol, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Diagnostic Uncertainty
Interventions: Targeted EHR-based Communication of Diagnostic Uncertainty (TECU); Behavioral
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Gene Mutation-Related Cancer, Genetic Predisposition
Interventions: Genetic Information Assistant, Telegenetics with UVA genetic counselor; Other
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Cannabidiol Effects, Driving Performance
Interventions: Cannabidiol (CBD) Oil 300mg, Cannabidiol (CBD) Oil 150mg, Placebo Oil; Drug
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years to 30 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Immunoglobulin A Nephropathy (IgAN)
Interventions: zigakibart; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 5
States / cities: San Francisco, California • Denver, Colorado • Acworth, Georgia + 2 more

Conditions: Posttraumatic Stress Disorder (PTSD), Intrinsic and Novelty-related Sensory Cortical (SC) Disinhibition
Interventions: Alternating Current Stimulation (tACS), Sham for Transcranial Alternating Current Stimulation (tACS), Transcranial Random Noise stimulation (tRNS); Device
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 50 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions: Survey Administration, Theanine; Other · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: Duarte, California • Huntington Beach, California • Irvine, California

Conditions: Primary Hyperparathyroidism
Interventions: NIRAF-camera; Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Acute Myeloid Leukemia, Adult
Interventions: Revumenib, Placebo; Drug
Lead sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland; Other
Eligibility: 18 Years and older
Enrollment: 448 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 14
States / cities: Los Angeles, California • San Francisco, California • Jacksonville, Florida + 11 more

Conditions: Transtibial Amputation, Peripheral Artery Disease, Diabetes Mellitus
Interventions: Error-augmentation gait training, Error-correction gait training, Supervised walking; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 40 Years to 89 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 2
States / cities: Aurora, Colorado • Richmond, Virginia

Conditions: Non-Hodgkin Lymphoma, Large B-cell Lymphoma
Interventions: Axicabtagene Ciloleucel; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2038
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Hemophilia A
Interventions: Damoctocog alfa pegol (Jivi, Bay94-9027); Drug
Lead sponsor: Bayer; Industry
Eligibility: 7 Years to 12 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Loma Linda, California • New Brunswick, New Jersey

Conditions: Pneumococcal Disease
Interventions: PG4 Multivalent Vaccine, 20 Valent Pneumococcal Conjugate Vaccine (20vPnC); Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 4,670 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 37
States / cities: Birmingham, Alabama • Lake Forest, California • Walnut Creek, California + 29 more

Conditions: Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography, Echocardiography Test, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Observation Activity, Paclitaxel, Pembrolizumab, Pemetrexed Disodium, Questionnaire Administration; Procedure · Drug · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 1,210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 1150
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Gilbert, Arizona + 747 more

Conditions: Tauopathies
Interventions: 11C-HY-2-15 PET, brain MRI, Amyloid PET scan, Neurological assessments; Drug · Diagnostic Test · Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 40 Years to 80 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

New York Better Breathing Study

Rare Glycogen Storage Diseases Natural History Study

Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation

A Comparison of Neuromuscular Recruitment in Trained and Untrained Adults

A Pilot, Feasibility Study of Intermittent Caloric Restriction Plus Plant-based Diet in Cancer Patients Receiving Chemotherapy

Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia

Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg

A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring

A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)

Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries

Targeted EHR-based Communication of Diagnostic Uncertainty in the ED

Genetic Information Assistant in Telegenetics

The Effects of Cannabidiol on the Driving Performance of Healthy Adults by Dose and Sex

A Study to Assess the Effects of Zigakibart on IgA Nephropathy.

A Neurosensory Account of Anxiety and Stress (Study 1)

L-Theanine to Support Relaxation and Mood for Cancer Patients in Surveillance

NIRAF-camera Versus Conventional Surgery in Preoperative Imaging Negative Primary Hyperparathyroidism

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

Optimizing Gait Rehabilitation for Veterans With Non-traumatic Lower Limb Amputation

Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel

An Observational Study to Learn More About How Well Damoctocog Alfa Pegol Works in Previously Treated Children With Hemophilia A

A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to Adults

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15